Synta announces publication of clinical, non-clinical results of Ganetespib

Synta Pharmaceuticals announced publication of results from in vitro, in vivo, and translational clinical studies demonstrating the effect of ganetespib on the ability of tumors to grow new blood vessels. Ganetespib, a selective inhibitor of the Hsp90 chaperone protein in development by Synta, is being evaluated in over 20 clinical trials for different types of cancer, including a pivotal Phase 3 trial in non-small cell lung cancer. The results suggest targeting hsp90 may inhibit angiogenesis without tumor rebound effects associated with VEGF-targeted anti-angiogenic therapies

View Comments (0)